Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Lifespan Changes of the Human Brain In Alzheimer&apos, s Disease

  • Coupé, Pierrick
  • Lanuza, Enrique
  • Catheline, Gwenaelle
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Brain imaging studies have shown that slow and progressive cerebral atrophy characterized the development of Alzheimer's Disease (AD). Despite a large number of studies dedicated to AD, key questions about the lifespan evolution of AD biomarkers remain open. When does the AD model diverge from the normal aging model? What is the lifespan trajectory of imaging biomarkers for AD? How do the trajectories of biomarkers in AD differ from normal aging? To answer these questions, we proposed an innovative way by inferring brain structure model across the entire lifespan using a massive number of MRI (N = 4329). We compared the normal model based on 2944 control subjects with the pathological model based on 3262 patients (AD + Mild cognitive Impaired subjects) older than 55 years and controls younger than 55 years. Our study provides evidences of early divergence of the AD models from the normal aging trajectory before 40 years for the hippocampus, followed by the lateral ventricles and the amygdala around 40 years. Moreover, our lifespan model reveals the evolution of these biomarkers and suggests close abnormality evolution for the hippocampus and the amygdala, whereas trajectory of ventricular enlargement appears to follow an inverted U-shape. Finally, our models indicate that medial temporal lobe atrophy and ventricular enlargement are two mid-life physiopathological events characterizing AD brain., This work benefited from the support of the project DeepVolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX- 03-02, HL-MRI Project), Cluster of excellence CPU and the CNRS. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria y Competitividad. Moreover, this work is based on multiple samples. We wish to thank all investigators of these projects who collected these datasets and made them freely accessible. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). A listing of the participating sites and a complete listing of the study investigators can be found at https://research.cchmc.org/c-mind. The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). NDAR is a collaborative informatics system created by the National Institutes of Health to provide a national resource to support and accelerate research in autism. The NDAR dataset includes data from the NIH Pediatric MRI Data Repository created by the NIH MRI Study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

BEaST: Brain extraction based on nonlocal segmentation technique

  • Eskildsen, Simon F.
  • Coupé, Pierrick
  • Fonov, Vladimir
  • Leung, Kelvin K.
  • Guizard, Nicolas
  • Wassef, Shafik N.
  • Østergaard, Lasse Riis
  • Collins, D. Louis
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Alzheimer's Dis Neuroimaging
Brain extraction is an important step in the analysis of brain images. The variability in brain morphology and the difference in intensity characteristics due to imaging sequences make the development of a general purpose brain extraction algorithm challenging. To address this issue, we propose a new robust method (BEaST) dedicated to produce consistent and accurate brain extraction. This method is based on nonlocal segmentation embedded in a multi-resolution framework. A library of 80 priors is semi-automatically constructed from the NIH-sponsored MRI study of normal brain development, the International Consortium for Brain Mapping, and the Alzheimer's Disease Neuroimaging Initiative databases. In testing, a mean Dice similarity coefficient of 0.9834 ± 0.0053 was obtained when performing leave-one-out cross validation selecting only 20 priors from the library. Validation using the online Segmentation Validation Engine resulted in a top ranking position with a mean Dice coefficient of 0.9781 ± 0.0047. Robustness of BEaST is demonstrated on all baseline ADNI data, resulting in a very low failure rate. The segmentation accuracy of the method is better than two widely used publicly available methods and recent state-of-the-art hybrid approaches. BEaST provides results comparable to a recent label fusion approach, while being 40 times faster and requiring a much smaller library of priors., Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514, and the Dana Foundation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Hippocampal-amygdalo-ventricular atrophy score: Alzheimer disease detection using normative and pathological lifespan models

  • Coupé, Pierrick
  • Mansencal, Boris
  • Tourdias, Thomas
  • Catheline, Gwenaelle
  • Planche, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] In this article, we present an innovative MRI-based method for Alzheimer disease (AD) detection and mild cognitive impairment (MCI) prognostic, using lifespan trajectories of brain structures. After a full screening of the most discriminant structures between AD and normal aging based on MRI volumetric analysis of 3,032 subjects, we propose a novel Hippocampal-Amygdalo-Ventricular Atrophy score (HAVAs) based on normative lifespan models and AD lifespan models. During a validation on three external datasets on 1,039 subjects, our approach showed very accurate detection (AUC >= 94%) of patients with AD compared to control subjects and accurate discrimination (AUC = 78%) between progressive MCI and stable MCI (during a 3-year follow-up). Compared to normative modeling, classical machine learning methods and recent state-of-the-art deep learning methods, our method demonstrated better classification performance. Moreover, HAVAs simplicity makes it fully understandable and thus well-suited for clinical practice or future pharmaceutical trials., UK Alzheimer's Society, Grant/Award Number: RF116; GlaxoSmithKline, Grant/Award Number: 6GKC; Leon Levy Foundation; NIMH, Grant/Award Numbers: R03MH096321, K23MH087770; ABIDE; U.K. Engineering and Physical Sciences Research Council, Grant/Award Number: GR/S21533/02; Canadian Institutes of Health Research, Grant/Award Number: MOP-34996; Human Brain Project, Grant/Award Number: PO1MHO52176-11; Alzheimer Drug Discovery Foundation; Alzheimer Association; National Health and Medical Research Council of Australia, Grant/Award Number: 1011689; Science Industry Endowment Fund; Common-wealth Scientific Industrial Research Organization; OASIS Brains Datasets, Grant/Award Numbers: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584; NIH, Grant/Award Numbers: K01 AG030514, P30AG010129; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; National Institutes of Health, Grant/Award Number: U01 AG024904; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Institute on Drug Abuse; National Institute of Child Health and Human Development, Grant/Award Number: HHSN275200900018C; Ministerio de Ciencia e Innovacion, Grant/Award Number: PID2020-118608RB-I00; French National Research Agency, Grant/Award Number: ANR-18-CE45-0013
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

An Optimized PatchMatch for multi-scale and multi-feature label fusion

  • Giraud, Rémi
  • Ta, Vinh-Thong
  • Papadakis, Nicolas
  • Collins, Louis
  • Coupé Pierrick
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
  • Alzheimers Dis Neuroimaging Initia
Automatic segmentation methods are important tools for quantitative analysis of Magnetic Resonance Images (MRI). Recently, patch-based label fusion approaches have demonstrated state-of-the-art segmentation accuracy. In this paper, we introduce a new patch-based label fusion framework to perform segmentation of anatomical structures. The proposed approach uses an Optimized PAtchMatch Label fusion (OPAL) strategy that drastically reduces the computation time required for the search of similar patches. The reduced computation time of OPAL opens the way for new strategies and facilitates processing on large databases. In this paper, we investigate new perspectives offered by OPAL, by introducing a new multi-scale and multi-feature framework. During our validation on hippocampus segmentation we use two datasets: young adults in the ICBM cohort and elderly adults in the EADC-ADNI dataset. For both, OPAL is compared to state-of-the-art methods. Results show that OPAL obtained the highest median Dice coefficient (89.9% for ICBM and 90.1% for EADC-ADNI). Moreover, in both cases, OPAL produced a segmentation accuracy similar to inter-expert variability. On the EADC-ADNI dataset, we compare the hippocampal volumes obtained by manual and automatic segmentation. The volumes appear to be highly correlated that enables to perform more accurate separation of pathological populations. (C) 2015 Elsevier Inc. All rights reserved., This study has been carried out with financial support from the French State, managed by the French National Research Agency (ANR) in the frame of the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-03-02), Cluster of excellence CPU and TRAIL (HR-DTI ANR-10-LABX-57). We also thank Tong Tong and Daniel Rueckert for providing us complete results of the methods proposed in Tong et al. (2013), Sonia Tangaro and Marina Boccardi for providing us complete results of the method proposed in Tangaro et al. (2014), and Katherine Gray and Robin Wolz for providing us complete results of the LEAP method proposed in Gray et al. (2014). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by the Spanish grant TIN2013-43457-R from the Ministerio de Economia y competitividad, NIH grants P30AG010129, K01 AG030514 and the Dana Foundation.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Towards a Unified Analysis of Brain Maturation and Aging across the Entire Lifespan: A MRI Analysis

  • Coupé, Pierrick
  • Catheline, Gwenaelle
  • Lanuza, Enrique
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] There is no consensus in literature about lifespan brain maturation and senescence, mainly because previous lifespan studies have been performed on restricted age periods and/or with a limited number of scans, making results instable and their comparison very difficult. Moreover, the use of nonharmonized tools and different volumetric measurements lead to a great discrepancy in reported results. Thanks to the new paradigm of BigData sharing in neuroimaging and the last advances in image processing enabling to process baby as well as elderly scans with the same tool, new insights on brain maturation and aging can be obtained. This study presents brain volume trajectory over the entire lifespan using the largest age range to date (from few months of life to elderly) and one of the largest number of subjects (N=2,944). First, we found that white matter trajectory based on absolute and normalized volumes follows an inverted U-shape with a maturation peak around middle life. Second, we found that from 1 to 8-10 y there is an absolute gray matter (GM) increase related to body growth followed by a GM decrease. However, when normalized volumes were considered, GM continuously decreases all along the life. Finally, we found that this observation holds for almost all the considered subcortical structures except for amygdala which is rather stable and hippocampus which exhibits an inverted U-shape with a longer maturation period. By revealing the entire brain trajectory picture, a consensus can be drawn since most of the previously discussed discrepancies can be explained. Hum Brain Mapp 38:5501-5518, 2017. (C) 2017 Wiley Periodicals, Inc., French State (French National Research Ageny in the frame of the Investments for the future Program IdEx Bordeaux); Contract grant number: ANR-10-IDEX-03-02, HL-MRI Project; Contract grant sponsor: Cluster of excellence CPU and TRAIL (HR-DTI ANR-10-LABX-57); Contract grant sponsor: CNRS ("Defi imag'In and the dedicated volBrain support); Contract grant sponsor: Ministerio de Economia y competitividad (Spanish); Contract grant number: TIN2013-43457-R; Contract grant sponsor: National Institute of Child Health and Human Development; Contract grant number: HHSN275200900018C; Contract grant sponsors: National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke; Contract grant numbers: N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320; Contract grant sponsor: National Institutes of Health; Contract grant number: U01 AG024904; Contract grant sponsor: National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering (ADNI); Contract grant sponsor: NIH; Contract grant number: P30AG010129, K01 AG030514; Contract grant sponsor: Dana Foundation; Contract grant sponsor: OASIS project (OASIS data); Contract grant numbers: P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584; Contract grant sponsor: Common-wealth Scientific Industrial Research Organization (a publicly funded government research organization); Contract grant sponsor: Science Industry Endowment Fund, National Health and Medical Research Council of Australia; Contract grant number: 1011689; Contract grant sponsors: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation; Contract grant sponsor: Human Brain Project; Contract grant number: PO1MHO52176-11 (ICBM, P.I. Dr John Mazziotta); Contract grant sponsor: Canadian Institutes of Health Research; Contract grant number: MOP-34996; Contract grant sponsor: U.K. Engineering and Physical Sciences Research Council (EPSRC); Contract grant number: GR/S21533/02; Contract grant sponsor: ABIDE funding resources; Contract grant sponsor: NIMH; Contract grant number: K23MH087770; Contract grant sponsor: Leon Levy Foundation; Contract grant sponsor: NIMH award to MPM; Contract grant number: R03MH096321
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

AssemblyNet: A large ensemble of CNNs for 3D whole brain MRI segmentation

  • Coupé, Pierrick
  • Mansencal, Boris
  • Clement, Michael
  • Giraud, Rémi
  • Denis de Senneville, Baudouin
  • Ta, Vinh-Thong
  • Lepetit, Vincent
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
[EN] Whole brain segmentation of fine-grained structures using deep learning (DL) is a very challenging task since the number of anatomical labels is very high compared to the number of available training images. To address this problem, previous DL methods proposed to use a single convolution neural network (CNN) or few independent CNNs. In this paper, we present a novel ensemble method based on a large number of CNNs processing different overlapping brain areas. Inspired by parliamentary decision-making systems, we propose a framework called AssemblyNet, made of two "assemblies" of U-Nets. Such a parliamentary system is capable of dealing with complex decisions, unseen problem and reaching a relevant consensus. AssemblyNet introduces sharing of knowledge among neighboring U-Nets, an "amendment" procedure made by the second assembly at higher-resolution to refine the decision taken by the first one, and a final decision obtained by majority voting. During our validation, AssemblyNet showed competitive performance compared to state-of-the-art methods such as U-Net, Joint label fusion and SLANT. Moreover, we investigated the scan-rescan consistency and the robustness to disease effects of our method. These experiences demonstrated the reliability of AssemblyNet. Finally, we showed the interest of using semi-supervised learning to improve the performance of our method., This work benefited from the support of the project DeepvolBrain of the French National Research Agency (ANR-18-CE45-0013). This study was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57 for the BigDataBrain project. Moreover, we thank the Investments for the future Program IdEx Bordeaux (ANR-10-IDEX-0 3-02, HL-MRI Project), Cluster of excellence CPU and the CNRS/INSERM for the DeepMultiBrain project. This study has been also supported by the DPI2017-87743-R grant from the Spanish Ministerio de Economia, Industria Competitividad. The C-MIND data used in the preparation of this article were obtained from the C-MIND Data Repository (accessed in Feb 2015) created by the C-MIND study of Normal Brain Development. This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by Cincinnati Children's Hospital Medical Center and UCLA and supported by the National Institute of Child Health and Human Development (Contract #s HHSN275200900018C). The NDAR data used in the preparation of this manuscript were obtained from the NIH-supported National Database for Autism Research (NDAR). This is a multisite, longitudinal study of typically developing children from ages newborn through young adulthood conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01- HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete listing of the study investigators can be found at http://pediatricmri.nih.gov/nihpd/info/participating_centers.html. The ADNI data used in the preparation of this manuscript were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation. The OASIS data used in the preparation of this manuscript were obtained from the OASIS project funded by grants P50 AG05681, P01 AG03991, R01 AG021910, P50 MH071616, U24 RR021382, R01 MH56584. The AIBL data used in the preparation of this manuscript were obtained from the AIBL study of ageing funded by the Common-wealth Scientific Industrial Research Organization (CSIRO; a publicly funded government research organization), Science Industry Endowment Fund, National Health and Medical Research Council of Australia (project grant 1011689), Alzheimer's Association, Alzheimer's Drug Discovery Foundation, and an anonymous foundation. The ICBM data used in the preparation of this manuscript were supported by Human Brain Project grant PO1MHO52176-11 (ICBM, P.I. Dr John Mazziotta) and Canadian Institutes of Health Research grant MOP-34996. The IXI data used in the preparation of this manuscript were supported by the U.K. Engineering and Physical Sciences Research Council (EPSRC) GR/S21533/02. ABIDE primary support for the work by Adriana Di Martino was provided by the NIMH (K23MH087770) and the Leon Levy Foundation. Primary support for the work by Michael P. Milham and the INDI team was provided by gifts from Joseph P. Healy and the Stavros Niarchos Foundation to the Child Mind Institute, as well as by an NIMH award to MPM (R03MH096321).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Scoring by nonlocal image patch estimator for early detection of Alzheimer&apos, s disease

  • Coupé, Pierrick
  • Eskildsen, Simon F.
  • Fonov, Vladirmir S.
  • Pruessner, Jens C.
  • Allard, Michèle
  • Collins, Louis D.
  • Manjón Herrera, José Vicente|||0000-0001-6640-927X
Detection of Alzheimer's disease (AD) at the first stages of the pathology is an important task to accelerate the development of new therapies and improve treatment. Compared to AD detection, the prediction of AD using structural MRI at the mild cognitive impairment (MCI) or pre-MCI stage is more complex because the associated anatomical changes are more subtle. In this study, we analyzed the capability of a recently proposed method, SNIPE (Scoring by Nonlocal Image Patch Estimator), to predict AD by analyzing entorhinal cortex (EC) and hippocampus (HC) scoring over the entire ADNI database (834 scans). Detection (AD vs. CN) and prediction (progressive - pMCI vs. stable - sMCI) efficiency of SNIPE were studied using volumetric and grading biomarkers. First, our results indicate that grading-based biomarkers are more relevant for prediction than volume-based biomarkers. Second, we show that HC-based biomarkers are more important than EC-based biomarkers for prediction. Third, we demonstrate that the results obtained by SNIPE are similar to or better than results obtained in an independent study using HC volume, cortical thickness, and tensor-based morphometry, individually and in combination. Fourth, a comparison of new patch-based methods shows that the nonlocal redundancy strategy involved in SNIPE obtained similar results to a new local sparse-based approach. Finally, we present the first results of patch-based morphometry to illustrate the progression of the pathology., We wish to thank Dr. Robin Wolz for providing the list of ADNI subjects used in his study, which allowed us to perform the presented method comparison. We also want to thank the Canadian Institutes of Health Research (MOP-111169) and the Fonds de la recherche en sante du Quebec. Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). The ADNI is funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics NV, Johnson & Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Schering-Plough, Synarc Inc., as well as nonprofit partners, the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U. S. Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study was coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30AG010129, K01 AG030514 and the Dana Foundation and also by the Spanish grant TIN2011-26727 from the Ministerio de Ciencia e Innovacion.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Tractography of the uncinate fasciculus and the posterior cingulate fasciculus in patients with mild cognitive impairment and Alzheimer disease, Tractografía del fascículo uncinado y el fascículo uncinado posterior en pacientes con deterioro cognitivo leve y enfermedad de Alzheimer

  • Larroza Santacruz, Andrés Martín
  • D'Ocón Alcañiz. Víctor
  • Arana Fernandez de Moya, Estanislao
  • Moratal, David|||0000-0002-2825-3646
  • Alzheimers Dis Neuroimaging Initia
[EN] Introduction: Brain tractography is a non-invasive medical imaging technique which enables in vivo visualisation and various types of quantitative studies of white matter fibre tracts connecting different parts of the brain. We completed a quantitative study using brain tractography with diffusion tensor imaging in patients with mild cognitive impairment, patients with Alzheimer disease, and normal controls, in order to analyse the reproducibility and validity of the results. Subjects and methods: Fractional anisotropy (FA) and mean diffusivity (MD) were measured across the uncinate fasciculus and the posterior cingulate fasciculus in images, obtained from a database and a research centre, representing 52 subjects distributed among the 3 study groups. Two observers took the measurements twice in order to evaluate intra- and inter-observer reproducibility. Results: Measurements of FA and MD of the uncinate fasciculus delivered an intraclass correlation coefficient above 0.9; ICC was above 0.68 for the posterior cingulate fasciculus. Patients with Alzheimer disease showed lower values of FA and higher MD values in the right uncinate fasciculus in images from the research centre. A comparison of the measurements from the 2 centres revealed significant differences. Conclusion: We established a reproducible methodology for performing tractography of the tracts in question. FA and MD indexes may serve as early indicators of Alzheimer disease. The type of equipment and the method used to acquire images must be considered because they may alter results as shown by comparing the 2 data sets in this study., [ES] Introducción: La tractografía cerebral es una técnica que permite visualizar los fascículos de sustancia blanca que conectan distintas partes del cerebro y realizar estudios cuantitativos de diversa índole sobre ellos. En este trabajo de investigación se realizó un estudio cuantitativo por tractografía cerebral mediante imágenes de resonancia magnética potenciadas en difusión en pacientes con deterioro cognitivo leve, enfermedad de Alzheimer y controles normales, con el fin de analizar la reproducibilidad y validez de los resultados. Sujetos y métodos: Se realizaron mediciones de anisotropía fraccional (FA) y difusividad media (MD) en el fascículo uncinado y el fascículo cingulado posterior, en imágenes obtenidas de una base de datos y de un centro de investigación, en 52 sujetos distribuidos en los 3 grupos de interés. Dos observadores realizaron las mediciones 2 veces para evaluar la reproducibilidad intra- e interobservador. Resultados: En el estudio de reproducibilidad se obtuvieron coeficientes de correlación intraclase superior a 0,9 para las medidas de FA y MD del fascículo uncinado, y mayor de 0,68 para las del fascículo cingulado posterior. Los pacientes con enfermedad de Alzheimer mostraron menores valores de FA y mayores valores de MD para el fascículo uncinado derecho correspondiente al centro de investigación. Existieron diferencias significativas en la comparación entre los datos de la base de datos y los del centro de investigación. Conclusiones: Se estableció una metodología reproducible para realizar tractografía en los fascículos estudiados. Los índices de FA y MD podrían ser indicadores tempranos de la enfermedad de Alzheimer, siendo necesario considerar el equipo y el método de adquisición de imágenes ya que pueden influir en los resultados como se comprobó en la comparación entre los 2 conjuntos de datos empleados. © 2012 Sociedad Espanola ˜ de Neurología. Publicado por Elsevier España, S.L. Todos los derechos reservados., A part of the data used in this study was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI), (National Institutes of Health Grant U01 AG024904). The ADNI consortium is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and by generous contributions from Abbott; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AustraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; BristolMyers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provide funding to support clinical ADNI locations in Canada. Contributions from the private sector are channelled through the Foundation for the National Institutes of Health (www.fnih.org). The organisation providing the framework for this consortium is the Northern California Institute for Research and Education; the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data were provided by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This study also received financing in the form of NIH grants P30 AG010129 and K01 AG030514.